J. Jack Lee

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/224551/j-jack-lee-publications-by-year.pdf
Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

478 papers	38,623 citations	98 h-index	183 g-index
511 ext. papers	45,192 ext. citations	6.9 avg, IF	7.51 L-index

#	Paper	IF	Citations
478	Surgical outcomes after nivolumab or nivolumab with ipilimumab treatment in patients with non-small cell lung cancer.. *Journal of Thoracic and Cardiovascular Surgery*, **2022**,	1.5	3
477	Phase II Clinical Trial of Neoadjuvant and Adjuvant Pembrolizumab in Resectable Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma.. *Clinical Cancer Research*, **2022**, 28, 1345-1352	12.9	3
476	MTAP deficiency creates an exploitable target for antifolate therapy in 9p21-loss cancers.. *Nature Communications*, **2022**, 13, 1797	17.4	0
475	/LKB1 Mutations in NSCLC Are Associated with KEAP1/NRF2-Dependent Radiotherapy Resistance Targetable by Glutaminase Inhibition. *Clinical Cancer Research*, **2021**, 27, 1720-1733	12.9	9
474	Inferential Frameworks for Clinical Trials **2021**, 1-30		
473	Cross-Site Concordance Evaluation of Tumor DNA and RNA Sequencing Platforms for the CIMAC-CIDC Network. *Clinical Cancer Research*, **2021**, 27, 5049-5061	12.9	
472	Cold and heterogeneous T cell repertoire is associated with copy number aberrations and loss of immune genes in small-cell lung cancer. *Nature Communications*, **2021**, 12, 6655	17.4	1
471	Molecular profiling of advanced malignancies guides first-line N-of-1 treatments in the I-PREDICT treatment-naïve study. *Genome Medicine*, **2021**, 13, 155	14.4	8
470	Efficacy of Targeted Inhibitors in Metastatic Lung Squamous Cell Carcinoma With or Alterations. *JTO Clinical and Research Reports*, **2021**, 2, 100237	1.4	0
469	An analysis of research biopsy core variability from over 5000 prospectively collected core samples. *Npj Precision Oncology*, **2021**, 5, 94	9.8	0
468	The Reality of Randomized Controlled Trials for Assessing the Benefit of Proton Therapy: Critically Examining the Intent-to-Treat Principle in the Presence of Insurance Denial. *Advances in Radiation Oncology*, **2021**, 6, 100635	3.3	0
467	Outcomes of patients with oropharyngeal squamous cell carcinoma treated with induction chemotherapy followed by concurrent chemoradiation compared with those treated with concurrent chemoradiation. *Cancer*, **2021**, 127, 2916-2925	6.4	1
466	Immuno-profiling and cellular spatial analysis using five immune oncology multiplex immunofluorescence panels for paraffin tumor tissue. *Scientific Reports*, **2021**, 11, 8511	4.9	7
465	Incorporating historical information to improve phase I clinical trials. *Pharmaceutical Statistics*, **2021** , 20, 1017-1034	1	3
464	Genotype-Specific Differences in Circulating Tumor DNA Levels in Advanced NSCLC. *Journal of Thoracic Oncology*, **2021**, 16, 601-609	8.9	11
463	Immune evasion in HPV head and neck precancer-cancer transition is driven by an aneuploid switch involving chromosome 9p loss. *Proceedings of the National Academy of Sciences of the United States of America*, **2021**, 118,	11.5	6
462	Immune evolution from preneoplasia to invasive lung adenocarcinomas and underlying molecular features. *Nature Communications*, **2021**, 12, 2722	17.4	16

461	The use of local and nonlocal priors in Bayesian test-based monitoring for single-arm phase II clinical trials. *Pharmaceutical Statistics*, **2021**, 20, 1183-1199	1	0
460	IPDfromKM: reconstruct individual patient data from published Kaplan-Meier survival curves. *BMC Medical Research Methodology*, **2021**, 21, 111	4.7	20
459	Naproxen chemoprevention promotes immune activation in Lynch syndrome colorectal mucosa. *Gut*, **2021**, 70, 555-566	19.2	10
458	Female Gender Predicts Augmented Immune Infiltration in Lung Adenocarcinoma. *Clinical Lung Cancer*, **2021**, 22, e415-e424	4.9	5
457	Risk Factors for and Time to Recurrence of Symptomatic Malignant Pleural Effusion in Patients With Metastatic Non-Small Cell Lung Cancer with EGFR or ALK Mutations. *Chest*, **2021**, 159, 1256-1264	5.3	5
456	Proteogenomic Analysis of Salivary Adenoid Cystic Carcinomas Defines Molecular Subtypes and Identifies Therapeutic Targets. *Clinical Cancer Research*, **2021**, 27, 852-864	12.9	12
455	A comparative study of Bayesian optimal interval (BOIN) design with interval 3+3 (i3+3) design for phase I oncology dose-finding trials. *Statistics in Biopharmaceutical Research*, **2021**, 13, 147-155	1.2	0
454	Evolution of DNA methylome from precancerous lesions to invasive lung adenocarcinomas. *Nature Communications*, **2021**, 12, 687	17.4	9
453	BOIN Suite: A Software Platform to Design and Implement Novel Early-Phase Clinical Trials. *JCO Clinical Cancer Informatics*, **2021**, 5, 91-101	5.2	7
452	Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. *Nature Medicine*, **2021**, 27, 504-514	50.5	105
451	Evaluating Bayesian adaptive randomization procedures with adaptive clip methods for multi-arm trials. *Statistical Methods in Medical Research*, **2021**, 30, 1273-1287	2.3	0
450	Multiplex Tissue Imaging Harmonization: A Multicenter Experience from CIMAC-CIDC Immuno-Oncology Biomarkers Network. *Clinical Cancer Research*, **2021**, 27, 5072-5083	12.9	3
449	Pembrolizumab in Patients with Refractory Cutaneous Squamous Cell Carcinoma: A Phase II Trial. *Advances in Therapy*, **2021**, 38, 4581-4591	4.1	2
448	Immune Profiling Mass Cytometry Assay Harmonization: Multicenter Experience from CIMAC-CIDC. *Clinical Cancer Research*, **2021**, 27, 5062-5071	12.9	1
447	Nodal immune flare mimics nodal disease progression following neoadjuvant immune checkpoint inhibitors in non-small cell lung cancer. *Nature Communications*, **2021**, 12, 5045	17.4	6
446	Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer **2021**, 9,		13
445	Principles and Reporting of Bayesian Trials. *Journal of Thoracic Oncology*, **2021**, 16, 30-36	8.9	0
444	Network for Biomarker Immunoprofiling for Cancer Immunotherapy: Cancer Immune Monitoring and Analysis Centers and Cancer Immunologic Data Commons (CIMAC-CIDC). *Clinical Cancer Research*, **2021**, 27, 5038-5048	12.9	1

443	CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinoma. *Cancer Immunology, Immunotherapy*, **2021**, 70, 1965-1976	7.4	1
442	The histologic phenotype of lung cancers is associated with transcriptomic features rather than genomic characteristics. *Nature Communications*, **2021**, 12, 7081	17.4	1
441	Cross-Site Concordance Evaluation of Tumor DNA and RNA Sequencing Platforms for the CIMAC-CIDC Network. *Clinical Cancer Research*, **2021**, 27, 5049-5061	12.9	2
440	Multiomics profiling of primary lung cancers and distant metastases reveals immunosuppression as a common characteristic of tumor cells with metastatic plasticity. *Genome Biology*, **2020**, 21, 271	18.3	13
439	Bayesian cluster hierarchical model for subgroup borrowing in the design and analysis of basket trials with binary endpoints. *Statistical Methods in Medical Research*, **2020**, 29, 2717-2732	2.3	7
438	A Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma. *Oncologist*, **2020**, 25, e1457-e1463	5.7	4
437	A Phase I/II Study of Neoadjuvant Cisplatin, Docetaxel, and Nintedanib for Resectable Non-Small Cell Lung Cancer. *Clinical Cancer Research*, **2020**, 26, 3525-3536	12.9	9
436	Agreement on Major Pathological Response in NSCLC Patients Receiving Neoadjuvant Chemotherapy. *Clinical Lung Cancer*, **2020**, 21, 341-348	4.9	27
435	The Prognostic and Therapeutic Role of Genomic Subtyping by Sequencing Tumor or Cell-Free DNA in Pulmonary Large-Cell Neuroendocrine Carcinoma. *Clinical Cancer Research*, **2020**, 26, 892-901	12.9	34
434	Heterogeneous antibodies against SARS-CoV-2 spike receptor binding domain and nucleocapsid with implications for COVID-19 immunity. *JCI Insight*, **2020**, 5,	9.9	88
433	Identification of biomarkers of immune checkpoint blockade efficacy in recurrent or refractory solid tumor malignancies. *Oncotarget*, **2020**, 11, 600-618	3.3	9
432	Evaluation of bias for outcome adaptive randomization designs with binary endpoints. *Statistics and Its Interface*, **2020**, 13, 287-315	0.4	1
431	Novel Bayesian Adaptive Designs and Their Applications in Cancer Clinical Trials. *Emerging Topics in Statistics and Biostatistics*, **2020**, 395-426	0.2	1
430	LKB1/STK11 Expression in Lung Adenocarcinoma and Associations With Patterns of Recurrence. *Annals of Thoracic Surgery*, **2020**, 110, 1131-1138	2.7	4
429	Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC. *Journal of Thoracic Oncology*, **2020**, 15, 1449-1459	8.9	49
428	Comprehensive T cell repertoire characterization of non-small cell lung cancer. *Nature Communications*, **2020**, 11, 603	17.4	67
427	Borrowing Strength and Borrowing Index for Bayesian Hierarchical Models. *Computational Statistics and Data Analysis*, **2020**, 144,	1.6	1
426	Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer: A Systematic Review and Meta-analysis. *JAMA Oncology*, **2020**, 6, 375-384	13.4	110

425	Response rates and survival to systemic therapy after immune checkpoint inhibitor failure in recurrent/metastatic head and neck squamous cell carcinoma. *Oral Oncology*, **2020**, 101, 104523	4.4	18
424	Concurrent use of aspirin with osimertinib is associated with improved survival in advanced EGFR-mutant non-small cell lung cancer. *Lung Cancer*, **2020**, 149, 33-40	5.9	2
423	Multicenter International Society for Immunotherapy of Cancer Study of the Consensus Immunoscore for the Prediction of Survival and Response to Chemotherapy in Stage III Colon Cancer. *Journal of Clinical Oncology*, **2020**, 38, 3638-3651	2.2	47
422	Evolution of Genomic and T-cell Repertoire Heterogeneity of Malignant Pleural Mesothelioma Under Dasatinib Treatment. *Clinical Cancer Research*, **2020**, 26, 5477-5486	12.9	12
421	Response adaptive randomization procedures in seamless phase II/III clinical trials. *Journal of Biopharmaceutical Statistics*, **2020**, 30, 3-17	1.3	0
420	F-fluorodeoxyglucose positron emission tomography correlates with tumor immunometabolic phenotypes in resected lung cancer. *Cancer Immunology, Immunotherapy*, **2020**, 69, 1519-1534	7.4	11
419	Phase I/II Trial of Immunotherapy With Durvalumab and Tremelimumab With Continuous or Intermittent MEK Inhibitor Selumetinib in NSCLC: Early Trial Report. *Clinical Lung Cancer*, **2020**, 21, 384-388	4.9	5
418	Impact of Neoadjuvant Durvalumab with or without Tremelimumab on CD8 Tumor Lymphocyte Density, Safety, and Efficacy in Patients with Oropharynx Cancer: CIAO Trial Results. *Clinical Cancer Research*, **2020**, 26, 3211-3219	12.9	28
417	A utility-based Bayesian optimal interval (U-BOIN) phase I/II design to identify the optimal biological dose for targeted and immune therapies. *Statistics in Medicine*, **2019**, 38, 5299-5316	2.3	23
416	Bayesian clinical trials at The University of Texas MD Anderson Cancer Center: An update. *Clinical Trials*, **2019**, 16, 645-656	2.2	7
415	Bayesian hierarchical classification and information sharing for clinical trials with subgroups and binary outcomes. *Biometrical Journal*, **2019**, 61, 1219-1231	1.5	8
414	Potential Influence on Clinical Trials of Long-Term Survivors of Stage IV Non-small cell Lung Cancer. *JNCI Cancer Spectrum*, **2019**, 3, pkz010	4.6	3
413	Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study. *Journal of Clinical Oncology*, **2019**, 37, 1558-1565	2.2	445
412	PD-L1 Expression, Tumor Mutational Burden, and Cancer Gene Mutations Are Stronger Predictors of Benefit from Immune Checkpoint Blockade than HLA Class I Genotype in Non-Small Cell Lung Cancer. *Journal of Thoracic Oncology*, **2019**, 14, 1021-1031	8.9	46
411	Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study. *Nature Medicine*, **2019**, 25, 744-750	50.5	240
410	Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial. *Nature Medicine*, **2019**, 25, 751-758	50.5	205
409	Inference and Decision Making for 21st-Century Drug Development and Approval. *American Statistician*, **2019**, 73, 319-327	5	18
408	Use of a Targeted Exome Next-Generation Sequencing Panel Offers Therapeutic Opportunity and Clinical Benefit in a Subset of Patients With Advanced Cancers. *JCO Precision Oncology*, **2019**, 3,	3.6	6

407	Tumor cellular proliferation is associated with enhanced immune checkpoint expression in stage I non-small cell lung cancer. *Journal of Thoracic and Cardiovascular Surgery*, **2019**, 158, 911-919.e6	1.5	11
406	Multi-region exome sequencing reveals genomic evolution from preneoplasia to lung adenocarcinoma. *Nature Communications*, **2019**, 10, 2978	17.4	43
405	Suppressed immune microenvironment and repertoire in brain metastases from patients with resected non-small-cell lung cancer. *Annals of Oncology*, **2019**, 30, 1521-1530	10.3	47
404	Oncogenic enhancer of zeste homolog 2 is an actionable target in patients with non-small cell lung cancer. *Cancer Medicine*, **2019**, 8, 6383-6392	4.8	8
403	Checkpoint inhibitors assessment in oropharynx cancer (CIAO): Safety and interim results.. *Journal of Clinical Oncology*, **2019**, 37, 6008-6008	2.2	13
402	A Collection of Statistical Methods for Precision Oncology.. *JCO Precision Oncology*, **2019**, 3, 1-3	3.6	
401	A Phase II Trial of Ziv-Aflibercept in Patients With Advanced Pancreatic Neuroendocrine Tumors. *Pancreas*, **2019**, 48, 381-386	2.6	4
400	Model-Assisted Designs for Early-Phase Clinical Trials: Simplicity Meets Superiority. *JCO Precision Oncology*, **2019**, 3,	3.6	14
399	Weekly paclitaxel, carboplatin, cetuximab, and cetuximab, docetaxel, cisplatin, and fluorouracil, followed by local therapy in previously untreated, locally advanced head and neck squamous cell carcinoma. *Annals of Oncology*, **2019**, 30, 471-477	10.3	12
398	Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16-Related Cancer: A Phase 2 Clinical Trial. *JAMA Oncology*, **2019**, 5, 67-73	13.4	217
397	Targeted Tissue and Cell-Free Tumor DNA Sequencing of Advanced Lung Squamous-Cell Carcinoma Reveals Clinically Significant Prevalence of Actionable Alterations. *Clinical Lung Cancer*, **2019**, 20, 30-36.e3	4.9	19
396	PI3-kinase pathway biomarkers in oral cancer and tumor immune cells. *Head and Neck*, **2019**, 41, 615-622	4.2	3
395	Erlotinib in the treatment of recurrent or metastatic cutaneous squamous cell carcinoma: A single-arm phase 2 clinical trial. *Cancer*, **2018**, 124, 2169-2173	6.4	60
394	A Randomized Multicenter Phase II Study of Docosahexaenoic Acid in Patients with a History of Breast Cancer, Premalignant Lesions, or Benign Breast Disease. *Cancer Prevention Research*, **2018**, 11, 203-214	3.2	11
393	Multiregion gene expression profiling reveals heterogeneity in molecular subtypes and immunotherapy response signatures in lung cancer. *Modern Pathology*, **2018**, 31, 947-955	9.8	35
392	Single Arm, Phase II Study of Cisplatin, Docetaxel, and Erlotinib in Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinomas. *Oncologist*, **2018**, 23, 526-e49	5.7	8
391	Met Receptor Tyrosine Kinase and Chemoprevention of Oral Cancer. *Journal of the National Cancer Institute*, **2018**, 110,	9.7	15
390	HLA class I antigen processing machinery (APM) component expression and PD-1:PD-L1 pathway activation in HIV-infected head and neck cancers. *Oral Oncology*, **2018**, 77, 92-97	4.4	6

389	Biomarker-Integrated Neoadjuvant Dasatinib Trial in Resectable Malignant Pleural Mesothelioma. *Journal of Thoracic Oncology*, **2018**, 13, 246-257	8.9	11
388	Immunohistochemical and Image Analysis-Based Study Shows That Several Immune Checkpoints are Co-expressed in Non-Small Cell Lung Carcinoma Tumors. *Journal of Thoracic Oncology*, **2018**, 13, 779-791	8.9	39
387	Controlled multi-arm platform design using predictive probability. *Statistical Methods in Medical Research*, **2018**, 27, 65-78	2.3	46
386	Comparing three regularization methods to avoid extreme allocation probability in response-adaptive randomization. *Journal of Biopharmaceutical Statistics*, **2018**, 28, 309-319	1.3	5
385	Distinct pattern of TP53 mutations in human immunodeficiency virus-related head and neck squamous cell carcinoma. *Cancer*, **2018**, 124, 84-94	6.4	12
384	Circulating tumor DNA analysis depicts subclonal architecture and genomic evolution of small cell lung cancer. *Nature Communications*, **2018**, 9, 3114	17.4	73
383	Effect of neoadjuvant chemotherapy on the immune microenvironment in non-small cell lung carcinomas as determined by multiplex immunofluorescence and image analysis approaches **2018**, 6, 48		76
382	Comparing Intensity-Modulated Proton Therapy With Intensity-Modulated Photon Therapy for Oropharyngeal Cancer: The Journey From Clinical Trial Concept to Activation. *Seminars in Radiation Oncology*, **2018**, 28, 108-113	5.5	20
381	Randomized phase II trial of cixutumumab alone or with cetuximab for refractory recurrent/metastatic head and neck squamous cell carcinoma. *Oral Oncology*, **2018**, 82, 83-90	4.4	15
380	Concomitant targeting of the mTOR/MAPK pathways: novel therapeutic strategy in subsets of -altered non-small cell lung cancer. *Oncotarget*, **2018**, 9, 33995-34008	3.3	5
379	Bayesian Adaptive Randomization and Trial Monitoring with Predictive Probability for Time-to-event Endpoint. *Statistics in Biosciences*, **2018**, 10, 420-438	1.5	5
378	Bayesian Adaptive Randomization Trial of Passive Scattering Proton Therapy and Intensity-Modulated Photon Radiotherapy for Locally Advanced Non-Small-Cell Lung Cancer. *Journal of Clinical Oncology*, **2018**, 36, 1813-1822	2.2	156
377	AACR White Paper: Shaping the Future of Cancer Prevention - A Roadmap for Advancing Science and Public Health. *Cancer Prevention Research*, **2018**, 11, 735-778	3.2	19
376	Biomarker Clinical Trials in Lung Cancer: Design, Logistics, Challenges, and Practical Considerations. *Journal of Thoracic Oncology*, **2018**, 13, 1625-1637	8.9	7
375	Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in -Mutant NSCLC. *Clinical Cancer Research*, **2018**, 24, 6195-6203	12.9	178
374	Mutations and PD-1 Inhibitor Resistance in -Mutant Lung Adenocarcinoma. *Cancer Discovery*, **2018**, 8, 822-835	24.4	648
373	Modifying the Clinical Research Infrastructure at a Dedicated Clinical Trials Unit: Assessment of Trial Development, Activation, and Participant Accrual. *Clinical Cancer Research*, **2017**, 23, 1407-1413	12.9	6
372	Clinical Trial Characteristics and Barriers to Participant Accrual: The MD Anderson Cancer Center Experience over 30 years, a Historical Foundation for Trial Improvement. *Clinical Cancer Research*, **2017**, 23, 1414-1421	12.9	21

371	Monotonic single-index models to assess drug interactions. *Statistics in Medicine*, **2017**, 36, 655-670	2.3	2
370	Activating NOTCH1 Mutations Define a Distinct Subgroup of Patients With Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver Metastasis, and Potential Responsiveness to Notch1 Inhibitors. *Journal of Clinical Oncology*, **2017**, 35, 352-360	2.2	104
369	BOP2: Bayesian optimal design for phase II clinical trials with simple and complex endpoints. *Statistics in Medicine*, **2017**, 36, 3302-3314	2.3	27
368	Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer. *Nature*, **2017**, 546, 498-503	50.4	1093
367	Comprehensive Analysis of the Discordance of EGFR Mutation Status between Tumor Tissues and Matched Circulating Tumor DNA in Advanced Non-Small Cell Lung Cancer. *Journal of Thoracic Oncology*, **2017**, 12, 1376-1387	8.9	29
366	The HGF/c-MET Pathway Is a Driver and Biomarker of VEGFR-inhibitor Resistance and Vascular Remodeling in Non-Small Cell Lung Cancer. *Clinical Cancer Research*, **2017**, 23, 5489-5501	12.9	41
365	High-Risk HPV, Biomarkers, and Outcome in Matched Cohorts of Head and Neck Cancer Patients Positive and Negative for HIV. *Molecular Cancer Research*, **2017**, 15, 179-188	6.6	14
364	Prognostic biomarkers in patients with human immunodeficiency virus-positive disease with head and neck squamous cell carcinoma. *Head and Neck*, **2017**, 39, 2433-2443	4.2	4
363	TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence. *Cancer Discovery*, **2017**, 7, 1088-1097	24.4	105
362	JAK1/STAT3 Activation through a Proinflammatory Cytokine Pathway Leads to Resistance to Molecularly Targeted Therapy in Non-Small Cell Lung Cancer. *Molecular Cancer Therapeutics*, **2017**, 16, 2234-2245	6.1	41
361	A second-order semiparametric method for survival analysis, with application to an acquired immune deficiency syndrome clinical trial study. *Journal of the Royal Statistical Society Series C: Applied Statistics*, **2017**, 66, 833-846	1.5	
360	A Plasma Biomarker Panel to Identify Surgically Resectable Early-Stage Pancreatic Cancer. *Journal of the National Cancer Institute*, **2017**, 109,	9.7	40
359	Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancer. *Lung Cancer*, **2017**, 112, 90-95	5.9	128
358	Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with Eblockers. *Science Translational Medicine*, **2017**, 9,	17.5	62
357	Next-Generation CDK2/9 Inhibitors and Anaphase Catastrophe in Lung Cancer. *Journal of the National Cancer Institute*, **2017**, 109,	9.7	31
356	A robust two-stage design identifying the optimal biological dose for phase I/II clinical trials. *Statistics in Medicine*, **2017**, 36, 27-42	2.3	14
355	Mutation profiles in early-stage lung squamous cell carcinoma with clinical follow-up and correlation with markers of immune function. *Annals of Oncology*, **2017**, 28, 83-89	10.3	63
354	Prediction-Oriented Marker Selection (PROMISE): With Application to High-Dimensional Regression. *Statistics in Biosciences*, **2017**, 9, 217-245	1.5	6

353	Analysis of Factors Affecting Successful Clinical Trial Enrollment in the Context of Three Prospective, Randomized, Controlled Trials. *International Journal of Radiation Oncology Biology Physics*, **2017**, 97, 770-777	4	11
352	Response to single-agent (SA) chemotherapy (CTx) after immunotherapy exposure in non-small cell lung cancer (NSCLC).. *Journal of Clinical Oncology*, **2017**, 35, 9083-9083	2.2	1
351	The ISG15-specific protease USP18 regulates stability of PTEN. *Oncotarget*, **2017**, 8, 3-14	3.3	28
350	Racial Differences in 20-Year Cardiovascular Mortality Risk Among Childhood and Young Adult Cancer Survivors. *Journal of Adolescent and Young Adult Oncology*, **2017**, 6, 414-421	2.2	10
349	Assessment of Drug Interactions with Repeated Measurements. *ICSA Book Series in Statistics*, **2017**, 277-291	0.1	
348	Bayesian Two-stage Biomarker-based Adaptive Design for Targeted Therapy Development. *Statistics in Biosciences*, **2016**, 8, 99-128	1.5	16
347	TP53 Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted Therapeutics. *Molecular Cancer Therapeutics*, **2016**, 15, 2475-2485	6.1	49
346	Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. *Lancet Oncology, The*, **2016**, 17, 1672-1682	21.7	548
345	Genomic heterogeneity of multiple synchronous lung cancer. *Nature Communications*, **2016**, 7, 13200	17.4	85
344	Association of Biomarker-Based Treatment Strategies With Response Rates and Progression-Free Survival in Refractory Malignant Neoplasms: A Meta-analysis. *JAMA Oncology*, **2016**, 2, 1452-1459	13.4	190
343	Interleukin-11 Receptor Is a Candidate Target for Ligand-Directed Therapy in Lung Cancer: Analysis of Clinical Samples and BMTP-11 Preclinical Activity. *American Journal of Pathology*, **2016**, 186, 2162-2170	5.8	13
342	Phase I biomarker modulation study of atorvastatin in women at increased risk for breast cancer. *Breast Cancer Research and Treatment*, **2016**, 158, 67-77	4.4	14
341	Image Analysis-based Assessment of PD-L1 and Tumor-Associated Immune Cells Density Supports Distinct Intratumoral Microenvironment Groups in Non-small Cell Lung Carcinoma Patients. *Clinical Cancer Research*, **2016**, 22, 6278-6289	12.9	96
340	Tissue Effects in a Randomized Controlled Trial of Short-term Finasteride in Early Prostate Cancer. *EBioMedicine*, **2016**, 7, 85-93	8.8	6
339	Two-stage marker-stratified clinical trial design in the presence of biomarker misclassification. *Journal of the Royal Statistical Society Series C: Applied Statistics*, **2016**, 65, 585-601	1.5	5
338	Intensity Modulated Proton Therapy Versus Intensity Modulated Photon Radiation Therapy for Oropharyngeal Cancer: First Comparative Results of Patient-Reported Outcomes. *International Journal of Radiation Oncology Biology Physics*, **2016**, 95, 1107-14	4	88
337	Response. *Journal of the National Cancer Institute*, **2016**, 108, djw001	9.7	
336	Modulation of EZH2 Expression by MEK-ERK or PI3K-AKT Signaling in Lung Cancer Is Dictated by Different KRAS Oncogene Mutations. *Cancer Research*, **2016**, 76, 675-85	10.1	68

335	Transforming Cancer Prevention through Precision Medicine and Immune-oncology. *Cancer Prevention Research*, **2016**, 9, 2-10	3.2	101
334	Erlotinib and the Risk of Oral Cancer: The Erlotinib Prevention of Oral Cancer (EPOC) Randomized Clinical Trial. *JAMA Oncology*, **2016**, 2, 209-16	13.4	89
333	Relation between the level of lymph node metastasis and survival in locally advanced head and neck squamous cell carcinoma. *Cancer*, **2016**, 122, 534-45	6.4	45
332	The tobacco-specific carcinogen-operated calcium channel promotes lung tumorigenesis via IGF2 exocytosis in lung epithelial cells. *Nature Communications*, **2016**, 7, 12961	17.4	15
331	Concordance of oral HPV prevalence between patients with oropharyngeal cancer and their partners. *Infectious Agents and Cancer*, **2016**, 11, 21	3.5	8
330	Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study. *Cancer Research*, **2016**, 76, 3690-701	10.1	154
329	Intensity-modulated proton beam therapy (IMPT) versus intensity-modulated photon therapy (IMRT) for patients with oropharynx cancer - A case matched analysis. *Radiotherapy and Oncology*, **2016**, 120, 48-55	5.3	129
328	The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer. *Journal of Clinical Oncology*, **2016**, 34, 3638-3647	2.2	108
327	Phase II study of gefitinib in patients with advanced salivary gland cancers. *Head and Neck*, **2015**, 37, 644-9	4.2	67
326	CD147 and Ki-67 overexpression confers poor prognosis in squamous cell carcinoma of oral tongue: a tissue microarray study. *Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology*, **2015**, 119, 553-65	2	22
325	Testing hypotheses about medical test accuracy: considerations for design and inference. *Journal of Applied Statistics*, **2015**, 42, 1106-1119	1	
324	Commentary on Hey and Kimmelman. *Clinical Trials*, **2015**, 12, 110-2	2.2	18
323	Challenges in initiating and conducting personalized cancer therapy trials: perspectives from WINTHER, a Worldwide Innovative Network (WIN) Consortium trial. *Annals of Oncology*, **2015**, 26, 1791-8	10.3	58
322	Relationship between tumor size and survival in non-small-cell lung cancer (NSCLC): an analysis of the surveillance, epidemiology, and end results (SEER) registry. *Journal of Thoracic Oncology*, **2015**, 10, 682-90	8.9	95
321	Targeting the insulin-like growth factor receptor and Src signaling network for the treatment of non-small cell lung cancer. *Molecular Cancer*, **2015**, 14, 113	42.1	30
320	New DNA methylation markers and global DNA hypomethylation are associated with oral cancer development. *Cancer Prevention Research*, **2015**, 8, 1027-35	3.2	45
319	Receptor tyrosine kinase EphA5 is a functional molecular target in human lung cancer. *Journal of Biological Chemistry*, **2015**, 290, 7345-59	5.4	29
318	Rational Clinical Experiment: Assessing Prior Probability and Its Impact on the Success of Phase II Clinical Trials. *Journal of Clinical Oncology*, **2015**, 33, 2914-9	2.2	2

317	Phase Ib Randomized, Double-Blinded, Placebo-Controlled, Dose Escalation Study of Polyphenon E in Patients with Barrett's Esophagus. *Cancer Prevention Research*, **2015**, 8, 1131-7	3.2	21
316	Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA Approval. *Journal of the National Cancer Institute*, **2015**, 107,	9.7	106
315	Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials. *Journal of Clinical Oncology*, **2015**, 33, 3817-25	2.2	286
314	Simulation study for evaluating the performance of response-adaptive randomization. *Contemporary Clinical Trials*, **2015**, 40, 15-25	2.3	11
313	Long-term results of a randomized phase III trial of TPF induction chemotherapy followed by surgery and radiation in locally advanced oral squamous cell carcinoma. *Oncotarget*, **2015**, 6, 18707-14	3.3	38
312	drexplorer: A tool to explore dose-response relationships and drug-drug interactions. *Bioinformatics*, **2015**, 31, 1692-4	7.2	19
311	Adding Erlotinib to Chemoradiation Improves Overall Survival but Not Progression-Free Survival in Stage III Non-Small Cell Lung Cancer. *International Journal of Radiation Oncology Biology Physics*, **2015**, 92, 317-24	4	44
310	Phase II trial of everolimus and erlotinib in patients with platinum-resistant recurrent and/or metastatic head and neck squamous cell carcinoma. *Annals of Oncology*, **2015**, 26, 1476-80	10.3	57
309	Comprehensive genomic characterization of head and neck squamous cell carcinomas. *Nature*, **2015** , 517, 576-82	50.4	2332
308	Prospective study comparing outcomes in patients with advanced malignancies on molecular alteration-matched versus non-matched therapy.. *Journal of Clinical Oncology*, **2015**, 33, 11019-11019	2.2	5
307	A simplified interventional mapping system (SIMS) for the selection of combinations of targeted treatments in non-small cell lung cancer. *Oncotarget*, **2015**, 6, 14139-52	3.3	19
306	Activation of insulin-like growth factor 1 receptor in patients with non-small cell lung cancer. *Oncotarget*, **2015**, 6, 16746-56	3.3	12
305	Expression pattern of FGFR2, Grb2 and Plcl1 acts as a novel prognostic marker of recurrence recurrence-free survival in lung adenocarcinoma. *American Journal of Cancer Research*, **2015**, 5, 3135-48	4.4	9
304	An overview of the design and conduct of the BATTLE trials. *Chinese Clinical Oncology*, **2015**, 4, 33	2.3	33
303	Cancer Chemoprevention **2015**, 809-824.e4		
302	Unique molecular landscapes in cancer: implications for individualized, curated drug combinations. *Cancer Research*, **2014**, 74, 7181-4	10.1	45
301	Increased leukocyte mitochondrial DNA copy number is associated with oral premalignant lesions: an epidemiology study. *Carcinogenesis*, **2014**, 35, 1760-4	4.6	15
300	Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. *Science*, **2014**, 346, 256-9	33.3	659

299	Phase I trial of cisplatin, pemetrexed, and imatinib mesylate in chemonaive patients with unresectable malignant pleural mesothelioma. *Clinical Lung Cancer*, **2014**, 15, 197-201	4.9	24
298	Elevated PDGFRB gene copy number gain is prognostic for improved survival outcomes in resected malignant pleural mesothelioma. *Annals of Diagnostic Pathology*, **2014**, 18, 140-5	2.2	9
297	Novel Statistical Models for NSCLC Clinical Trials **2014**, 488-504		1
296	Epidemiology of head and neck squamous cell cancer among HIV-infected patients. *Journal of Acquired Immune Deficiency Syndromes (1999)*, **2014**, 65, 603-10	3.1	45
295	Calibrating the prior distribution for a normal model with conjugate prior. *Journal of Statistical Computation and Simulation*, **2014**, 85, 3108-3128	0.9	1
294	Triple-negative breast cancer patients treated at MD Anderson Cancer Center in phase I trials: improved outcomes with combination chemotherapy and targeted agents. *Molecular Cancer Therapeutics*, **2014**, 13, 3175-84	6.1	26
293	Mutational landscape of aggressive cutaneous squamous cell carcinoma. *Clinical Cancer Research*, **2014**, 20, 6582-92	12.9	362
292	Outcome-adaptive randomization for a delayed outcome with a short-term predictor: imputation-based designs. *Statistics in Medicine*, **2014**, 33, 4029-42	2.3	6
291	Expression profiling stratifies mesothelioma tumors and signifies deregulation of spindle checkpoint pathway and microtubule network with therapeutic implications. *Annals of Oncology*, **2014**, 25, 1184-92	10.3	30
290	Adaptive Clinical Trials: Overview of Early-Phase Designs and Challenges. *Therapeutic Innovation and Regulatory Science*, **2014**, 48, 20-30	1.2	10
289	Adaptive designs for identifying optimal biological dose for molecularly targeted agents. *Clinical Trials*, **2014**, 11, 319-327	2.2	48
288	Prediction of survival in resected non-small cell lung cancer using a protein expression-based risk model: implications for personalized chemoprevention and therapy. *Clinical Cancer Research*, **2014**, 20, 1946-54	12.9	26
287	A phase I/II study combining erlotinib and dasatinib for non-small cell lung cancer. *Oncologist*, **2014**, 19, 1040-1	5.7	28
286	Membrane carbonic anhydrase IX expression and relapse risk in resected stage I-II non-small-cell lung cancer. *Journal of Thoracic Oncology*, **2014**, 9, 675-84	8.9	18
285	VEGF/VEGFR-2 upregulates EZH2 expression in lung adenocarcinoma cells and EZH2 depletion enhances the response to platinum-based and VEGFR-2-targeted therapy. *Clinical Cancer Research*, **2014**, 20, 3849-61	12.9	36
284	Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors. *Cell Reports*, **2014**, 6, 377-87	10.6	186
283	Prognostic implications of tumoral expression of insulin like growth factors 1 and 2 in patients with non-small-cell lung cancer. *Clinical Lung Cancer*, **2014**, 15, 213-21	4.9	19
282	Vandetanib and indwelling pleural catheter for non-small-cell lung cancer with recurrent malignant pleural effusion. *Clinical Lung Cancer*, **2014**, 15, 379-86	4.9	9

281	One step forward, two steps back. *Lancet Oncology, The*, **2014**, 15, 366-7	21.7	7
280	Unique molecular signatures as a hallmark of patients with metastatic breast cancer: implications for current treatment paradigms. *Oncotarget*, **2014**, 5, 2349-54	3.3	50
279	Adaptive clinical trial designs in oncology. *Chinese Clinical Oncology*, **2014**, 3,	2.3	5
278	ETS2 mediated tumor suppressive function and MET oncogene inhibition in human non-small cell lung cancer. *Clinical Cancer Research*, **2013**, 19, 3383-95	12.9	96
277	RE: Meta-analysis of the relationship between dose and benefit in phase I targeted agent trials. *Journal of the National Cancer Institute*, **2013**, 105, 833	9.7	
276	Bayesian two-step Lasso strategy for biomarker selection in personalized medicine development for time-to-event endpoints. *Contemporary Clinical Trials*, **2013**, 36, 642-50	2.3	23
275	A Bayesian decision-theoretic sequential response-adaptive randomization design. *Statistics in Medicine*, **2013**, 32, 1975-94	2.3	12
274	PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials. *Cancer Research*, **2013**, 73, 276-84	10.1	221
273	Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma. *Journal of Clinical Oncology*, **2013**, 31, 744-51	2.2	196
272	Optimal continuous-monitoring design of single-arm phase II trial based on the simulated annealing method. *Contemporary Clinical Trials*, **2013**, 35, 170-8	2.3	1
271	An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. *Clinical Cancer Research*, **2013**, 19, 279-90	12.9	649
270	Characterizing the molecular spatial and temporal field of injury in early-stage smoker non-small cell lung cancer patients after definitive surgery by expression profiling. *Cancer Prevention Research* , **2013**, 6, 8-17	3.2	29
269	CXCR2 expression in tumor cells is a poor prognostic factor and promotes invasion and metastasis in lung adenocarcinoma. *Cancer Research*, **2013**, 73, 571-82	10.1	114
268	Elevated cyclin D1 expression is predictive for a benefit from TPF induction chemotherapy in oral squamous cell carcinoma patients with advanced nodal disease. *Molecular Cancer Therapeutics*, **2013**, 12, 1112-21	6.1	28
267	Accelerated approval and breakthrough therapy designation: oncology drug development on speed?. *Clinical Cancer Research*, **2013**, 19, 4305-8	12.9	7
266	Comprehensive biomarker analysis and final efficacy results of sorafenib in the BATTLE trial. *Clinical Cancer Research*, **2013**, 19, 6967-75	12.9	49
265	EZH2 protein expression associates with the early pathogenesis, tumor progression, and prognosis of non-small cell lung carcinoma. *Clinical Cancer Research*, **2013**, 19, 6556-65	12.9	103
264	Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations. *Molecular Cancer Therapeutics*, **2013**, 12, 2857-63	6.1	35

263	Short telomere lengths in peripheral blood leukocytes are associated with an increased risk of oral premalignant lesion and oral squamous cell carcinoma. *Cancer*, **2013**, 119, 4277-83	6.4	27
262	Reply to A. Levy et al. *Journal of Clinical Oncology*, **2013**, 31, 396	2.2	4
261	Clinical and biomarker outcomes of the phase II vandetanib study from the BATTLE trial. *Journal of Thoracic Oncology*, **2013**, 8, 658-61	8.9	14
260	Computed tomography RECIST assessment of histopathologic response and prediction of survival in patients with resectable non-small-cell lung cancer after neoadjuvant chemotherapy. *Journal of Thoracic Oncology*, **2013**, 8, 222-8	8.9	72
259	Feasibility of image-guided transthoracic core-needle biopsy in the BATTLE lung trial. *Journal of Thoracic Oncology*, **2013**, 8, 436-42	8.9	72
258	BATTLE-2 program: A biomarker-integrated targeted therapy study in previously treated patients with advanced non-small cell lung cancer (NSCLC).. *Journal of Clinical Oncology*, **2013**, 31, TPS8118-TPS8118	2.2	4
257	P53 mutations in advanced cancers: clinical characteristics, outcomes, and correlation between progression-free survival and bevacizumab-containing therapy. *Oncotarget*, **2013**, 4, 705-14	3.3	87
256	Phase II trial design with Bayesian adaptive randomization and predictive probability. *Journal of the Royal Statistical Society Series C: Applied Statistics*, **2012**, 61, 219-35	1.5	44
255	Redesigning radiotherapy quality assurance: opportunities to develop an efficient, evidence-based system to support clinical trials--report of the National Cancer Institute Work Group on Radiotherapy Quality Assurance. *International Journal of Radiation Oncology Biology Physics*, **2012**, 83, 782-90	4	50
254	Influence of chemotherapy on EGFR mutation status among patients with non-small-cell lung cancer. *Journal of Clinical Oncology*, **2012**, 30, 3077-83	2.2	154
253	Phase I clinical trial of systemically administered TUSC2(FUS1)-nanoparticles mediating functional gene transfer in humans. *PLoS ONE*, **2012**, 7, e34833	3.7	119
252	Bayesian clinical trials in action. *Statistics in Medicine*, **2012**, 31, 2955-72	2.3	98
251	PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. *Journal of Clinical Oncology*, **2012**, 30, 777-82	2.2	355
250	Prognostic impact of insulin receptor expression on survival of patients with nonsmall cell lung cancer. *Cancer*, **2012**, 118, 2454-65	6.4	51
249	Histologic patterns and molecular characteristics of lung adenocarcinoma associated with clinical outcome. *Cancer*, **2012**, 118, 2889-99	6.4	75
248	Epidermal growth factor receptor and K-Ras mutations and resistance of lung cancer to insulin-like growth factor 1 receptor tyrosine kinase inhibitors. *Cancer*, **2012**, 118, 3993-4003	6.4	34
247	Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. *Journal of the National Cancer Institute*, **2012**, 104, 228-39	9.7	331
246	Worth adapting? Revisiting the usefulness of outcome-adaptive randomization. *Clinical Cancer Research*, **2012**, 18, 4498-507	12.9	45

245	Genetic variants in the PI3K/PTEN/AKT/mTOR pathway predict head and neck cancer patient second primary tumor/recurrence risk and response to retinoid chemoprevention. *Clinical Cancer Research*, **2012**, 18, 3705-13	12.9	45
244	Change in tumor size by RECIST correlates linearly with overall survival in phase I oncology studies. *Journal of Clinical Oncology*, **2012**, 30, 2684-90	2.2	71
243	The impact of phosphorylated AMP-activated protein kinase expression on lung cancer survival. *Annals of Oncology*, **2012**, 23, 78-85	10.3	40
242	Tissue platinum concentration and tumor response in non-small-cell lung cancer. *Journal of Clinical Oncology*, **2012**, 30, 3345-52	2.2	69
241	Loss of heterozygosity (LOH) profiles--validated risk predictors for progression to oral cancer. *Cancer Prevention Research*, **2012**, 5, 1081-9	3.2	132
240	G-protein coupled receptor family C, group 5, member A (GPRC5A) expression is decreased in the adjacent field and normal bronchial epithelia of patients with chronic obstructive pulmonary disease and non-small-cell lung cancer. *Journal of Thoracic Oncology*, **2012**, 7, 1747-1754	8.9	38
239	Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy. *Journal of Thoracic Oncology*, **2012**, 7, 825-32	8.9	167
238	Accuracy of in vivo multimodal optical imaging for detection of oral neoplasia. *Cancer Prevention Research*, **2012**, 5, 801-9	3.2	82
237	Clinical outcomes and biomarker profiles of elderly pretreated NSCLC patients from the BATTLE trial. *Journal of Thoracic Oncology*, **2012**, 7, 1645-52	8.9	16
236	High expression of folate receptor alpha in lung cancer correlates with adenocarcinoma histology and EGFR [corrected] mutation. *Journal of Thoracic Oncology*, **2012**, 7, 833-40	8.9	87
235	Antitumor activity of AZ64 via G2/M arrest in non-small cell lung cancer. *International Journal of Oncology*, **2012**, 41, 1798-808	4.4	10
234	PIK3CA mutations in advanced cancers: characteristics and outcomes. *Oncotarget*, **2012**, 3, 1566-75	3.3	71
233	The BATTLE to personalize lung cancer prevention through reverse migration. *Cancer Prevention Research*, **2011**, 4, 962-72	3.2	40
232	Elevated BCRP/ABCG2 expression confers acquired resistance to gefitinib in wild-type EGFR-expressing cells. *PLoS ONE*, **2011**, 6, e21428	3.7	67
231	PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers. *PLoS ONE*, **2011**, 6, e22769	3.7	153
230	Global assessment of genetic variation influencing response to retinoid chemoprevention in head and neck cancer patients. *Cancer Prevention Research*, **2011**, 4, 185-93	3.2	34
229	Phase II trials of imatinib mesylate and docetaxel in patients with metastatic non-small cell lung cancer and head and neck squamous cell carcinoma. *Journal of Thoracic Oncology*, **2011**, 6, 2104-11	8.9	22
228	Frequent expression of MAGE1 tumor antigens in bronchial epithelium of smokers without lung cancer. *Experimental and Therapeutic Medicine*, **2011**, 2, 137-142	2.1	3

227	KiSS1 mediates platinum sensitivity and metastasis suppression in head and neck squamous cell carcinoma. *Oncogene*, **2011**, 30, 3163-73	9.2	28
226	Canadian Optically-guided approach for Oral Lesions Surgical (COOLS) trial: study protocol for a randomized controlled trial. *BMC Cancer*, **2011**, 11, 462	4.8	26
225	Immunohistochemical overexpression of platelet-derived growth factor receptor-beta (PDGFR-β) is associated with PDGFRB gene copy number gain in sarcomatoid non-small-cell lung cancer. *Clinical Lung Cancer*, **2011**, 12, 369-74	4.9	26
224	The BATTLE trial: personalizing therapy for lung cancer. *Cancer Discovery*, **2011**, 1, 44-53	24.4	660
223	Differential impacts of insulin-like growth factor-binding protein-3 (IGFBP-3) in epithelial IGF-induced lung cancer development. *Endocrinology*, **2011**, 152, 2164-73	4.8	17
222	Cotargeting cyclin D1 starts a new chapter in lung cancer prevention and therapy. *Cancer Prevention Research*, **2011**, 4, 779-82	3.2	13
221	Rebuttal to the Response of Chou. *Cancer Research*, **2011**, 71, 2798-2800	10.1	2
220	Abnormalities of the TITF-1 lineage-specific oncogene in NSCLC: implications in lung cancer pathogenesis and prognosis. *Clinical Cancer Research*, **2011**, 17, 2434-43	12.9	65
219	Demystify statistical significance--time to move on from the p value to bayesian analysis. *Journal of the National Cancer Institute*, **2011**, 103, 2-3	9.7	21
218	A five-gene and corresponding protein signature for stage-I lung adenocarcinoma prognosis. *Clinical Cancer Research*, **2011**, 17, 1490-501	12.9	55
217	Combined Treatment of Pancreatic Cancer with Mithramycin A and Tolfenamic Acid Promotes Sp1 Degradation and Synergistic Antitumor Activity. Response. *Cancer Research*, **2011**, 71, 2794-2795	10.1	3
216	A randomized controlled trial of celecoxib to prevent recurrence of nonmuscle-invasive bladder cancer. *Cancer Prevention Research*, **2011**, 4, 1580-9	3.2	36
215	Gene expression profiling predicts the development of oral cancer. *Cancer Prevention Research*, **2011**, 4, 218-29	3.2	95
214	DNA repair biomarker profiling of head and neck cancer: Ku80 expression predicts locoregional failure and death following radiotherapy. *Clinical Cancer Research*, **2011**, 17, 2035-43	12.9	74
213	Increased VEGFR-2 gene copy is associated with chemoresistance and shorter survival in patients with non-small-cell lung carcinoma who receive adjuvant chemotherapy. *Cancer Research*, **2011**, 71, 5512-21	10.1	48
212	Phase II Trials with Anticancer Agents **2011**, 141-161		
211	Epidermal growth factor receptor regulates MET levels and invasiveness through hypoxia-inducible factor-1alpha in non-small cell lung cancer cells. *Oncogene*, **2010**, 29, 2616-27	9.2	66
210	CR represents an early index of potential long survival in multiple myeloma. *Bone Marrow Transplantation*, **2010**, 45, 498-504	4.4	40

209	Emax model and interaction index for assessing drug interaction in combination studies. *Frontiers in Bioscience - Elite*, **2010**, 2, 582-601	1.6	2
208	Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trial. *Journal of Clinical Oncology*, **2010**, 28, 8-14	2.2	191
207	Biological activity of celecoxib in the bronchial epithelium of current and former smokers. *Cancer Prevention Research*, **2010**, 3, 148-59	3.2	43
206	Expression of interleukin-1 receptor-associated kinase-1 in non-small cell lung carcinoma and preneoplastic lesions. *Clinical Cancer Research*, **2010**, 16, 34-44	12.9	26
205	Phase I oncology studies: evidence that in the era of targeted therapies patients on lower doses do not fare worse. *Clinical Cancer Research*, **2010**, 16, 1289-97	12.9	96
204	MicroRNA-related genetic variations as predictors for risk of second primary tumor and/or recurrence in patients with early-stage head and neck cancer. *Carcinogenesis*, **2010**, 31, 2118-23	4.6	45
203	Validation of a novel statistical model for assessing the synergy of combined-agent cancer chemoprevention. *Cancer Prevention Research*, **2010**, 3, 917-28	3.2	2
202	Genetic variations in regulator of G-protein signaling genes as susceptibility loci for second primary tumor/recurrence in head and neck squamous cell carcinoma. *Carcinogenesis*, **2010**, 31, 1755-61	4.6	20
201	Serum signature of hypoxia-regulated factors is associated with progression after induction therapy in head and neck squamous cell cancer. *Molecular Cancer Therapeutics*, **2010**, 9, 1755-63	6.1	40
200	Bayesian adaptive randomization designs for targeted agent development. *Clinical Trials*, **2010**, 7, 584-96	2.2	79
199	Mortality in the randomized, controlled lung intergroup trial of isotretinoin. *Cancer Prevention Research*, **2010**, 3, 738-44	3.2	9
198	Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer. *Journal of Clinical Oncology*, **2010**, 28, 193-201	2.2	123
197	Chemoradiotherapy with or without AE-941 in stage III non-small cell lung cancer: a randomized phase III trial. *Journal of the National Cancer Institute*, **2010**, 102, 859-65	9.7	57
196	Epidermal growth factor receptor expression and gene copy number in the risk of oral cancer. *Cancer Prevention Research*, **2010**, 3, 800-9	3.2	96
195	Comparison of multispectral wide-field optical imaging modalities to maximize image contrast for objective discrimination of oral neoplasia. *Journal of Biomedical Optics*, **2010**, 15, 066017	3.5	19
194	A simulation study for comparing testing statistics in response-adaptive randomization. *BMC Medical Research Methodology*, **2010**, 10, 48	4.7	10
193	Phase 2 study of carboplatin, docetaxel, and bevacizumab as frontline treatment for advanced nonsmall-cell lung cancer. *Cancer*, **2010**, 116, 2401-8	6.4	14
192	Genetic variation in MicroRNA genes and risk of oral premalignant lesions. *Molecular Carcinogenesis* , **2010**, 49, 183-9	5	80

191	Prospective imaging assessment of mortality risk after head-and-neck radiotherapy. *International Journal of Radiation Oncology Biology Physics*, **2010**, 78, 667-74	4	20
190	Applying Emax model and bivariate thin plate splines to assess drug interactions. *Frontiers in Bioscience - Elite*, **2010**, 2, 279-92	1.6	2
189	Phase II study of vinorelbine and docetaxel in the treatment of advanced non-small-cell lung cancer as frontline and second-line therapy. *American Journal of Clinical Oncology: Cancer Clinical Trials*, **2010**, 33, 148-52	2.7	7
188	A systems biology-based gene expression classifier of glioblastoma predicts survival with solid tumors. *PLoS ONE*, **2009**, 4, e6274	3.7	17
187	Cyclin D1 and cancer development in laryngeal premalignancy patients. *Cancer Prevention Research*, **2009**, 2, 14-21	3.2	39
186	Identification of gene signatures and molecular markers for human lung cancer prognosis using an in vitro lung carcinogenesis system. *Cancer Prevention Research*, **2009**, 2, 702-11	3.2	43
185	DeltaNp63 overexpression, alone and in combination with other biomarkers, predicts the development of oral cancer in patients with leukoplakia. *Clinical Cancer Research*, **2009**, 15, 6284-91	12.9	52
184	Durable long-term remission with chemotherapy alone for stage II to IV laryngeal cancer. *Journal of Clinical Oncology*, **2009**, 27, 1976-82	2.2	35
183	Revisiting stage IIIB and IV non-small cell lung cancer: analysis of the surveillance, epidemiology, and end results data. *Chest*, **2009**, 136, 701-709	5.3	91
182	Confidence Intervals of Interaction Index for Assessing Multiple Drug Interaction. *Statistics in Biopharmaceutical Research*, **2009**, 1, 4-17	1.2	30
181	Immunohistochemical expression of estrogen and progesterone receptors identifies a subset of NSCLCs and correlates with EGFR mutation. *Clinical Cancer Research*, **2009**, 15, 5359-68	12.9	131
180	Randomized trial of 13-cis retinoic acid compared with retinyl palmitate with or without beta-carotene in oral premalignancy. *Journal of Clinical Oncology*, **2009**, 27, 599-604	2.2	85
179	Elevated epithelial insulin-like growth factor expression is a risk factor for lung cancer development. *Cancer Research*, **2009**, 69, 7439-48	10.1	46
178	Bayesian clinical trials at the University of Texas M. D. Anderson Cancer Center. *Clinical Trials*, **2009**, 6, 205-16	2.2	85
177	Objective detection and delineation of oral neoplasia using autofluorescence imaging. *Cancer Prevention Research*, **2009**, 2, 423-31	3.2	128
176	Phase II randomized, placebo-controlled trial of green tea extract in patients with high-risk oral premalignant lesions. *Cancer Prevention Research*, **2009**, 2, 931-41	3.2	182
175	Melding a New 3-Dimensional Agarose Colony Assay with the E(max) Model to Determine the Effects of Drug Combinations on Cancer Cells. *Technology in Cancer Research and Treatment*, **2009**, 8, 163-76	2.7	2
174	High-dose fenretinide in oral leukoplakia. *Cancer Prevention Research*, **2009**, 2, 22-6	3.2	37

173	Novel susceptibility loci for second primary tumors/recurrence in head and neck cancer patients: large-scale evaluation of genetic variants. *Cancer Prevention Research*, **2009**, 2, 617-24	3.2	52
172	Response: Re: Dose Escalation Methods in Phase I Cancer Clinical Trials. *Journal of the National Cancer Institute*, **2009**, 101, 1733-1735	9.7	2
171	A phase 2 study of cetuximab in combination with docetaxel in chemotherapy-refractory/resistant patients with advanced nonsmall cell lung cancer. *Cancer*, **2009**, 115, 1713-22	6.4	31
170	Cyclooxygenase-2 gene polymorphisms reduce the risk of oral premalignant lesions. *Cancer*, **2009**, 115, 1498-506	6.4	18
169	Noninvasive evaluation of oral lesions using depth-sensitive optical spectroscopy. *Cancer*, **2009**, 115, 1669-79	6.4	80
168	Comparison of Bayesian Sample Size Criteria: ACC, ALC, and WOC. *Journal of Statistical Planning and Inference*, **2009**, 139, 4111-4122	0.8	16
167	Incidence, risk factors, and impact of severe neutropenia after hyperthermic intraperitoneal mitomycin C. *Annals of Surgical Oncology*, **2009**, 16, 2181-7	3.1	50
166	Prospective risk-adjusted [18F]Fluorodeoxyglucose positron emission tomography and computed tomography assessment of radiation response in head and neck cancer. *Journal of Clinical Oncology* , **2009**, 27, 2509-15	2.2	142
165	Dose escalation methods in phase I cancer clinical trials. *Journal of the National Cancer Institute*, **2009**, 101, 708-20	9.7	528
164	Phase I trial of weekly topotecan and gemcitabine in patients with solid tumors. *American Journal of Clinical Oncology: Cancer Clinical Trials*, **2009**, 32, 15-9	2.7	3
163	Genetic polymorphisms in double-strand break DNA repair genes associated with risk of oral premalignant lesions. *European Journal of Cancer*, **2008**, 44, 1603-11	7.5	24
162	Podoplanin: a novel marker for oral cancer risk in patients with oral premalignancy. *Journal of Clinical Oncology*, **2008**, 26, 354-60	2.2	157
161	Model diagnostic tests for selecting informative correlation structure in correlated data. *Biometrika* , **2008**, 95, 891-905	2	5
160	Pilot randomized phase II study of celecoxib in oral premalignant lesions. *Clinical Cancer Research*, **2008**, 14, 2095-101	12.9	81
159	Impact of smoking cessation on global gene expression in the bronchial epithelium of chronic smokers. *Cancer Prevention Research*, **2008**, 1, 112-8	3.2	61
158	Oral epithelium as a surrogate tissue for assessing smoking-induced molecular alterations in the lungs. *Cancer Prevention Research*, **2008**, 1, 39-44	3.2	69
157	Immunohistochemical expression of basic fibroblast growth factor and fibroblast growth factor receptors 1 and 2 in the pathogenesis of lung cancer. *Clinical Cancer Research*, **2008**, 14, 6014-22	12.9	96
156	Bayesian adaptive design for targeted therapy development in lung cancer--a step toward personalized medicine. *Clinical Trials*, **2008**, 5, 181-93	2.2	149

155	Cost-effectiveness of prostate cancer chemoprevention: a quality of life-years analysis. *Cancer*, **2008**, 112, 1058-65	6.4	50
154	Genetic variations in cell-cycle pathway and the risk of oral premalignant lesions. *Cancer*, **2008**, 113, 2488-95	6.4	17
153	A predictive probability design for phase II cancer clinical trials. *Clinical Trials*, **2008**, 5, 93-106	2.2	102
152	A semiparametric response surface model for assessing drug interaction. *Biometrics*, **2008**, 64, 396-405	1.8	25
151	Cancer Chemoprevention **2008**, 711-720		1
150	Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. *Journal of Clinical Oncology*, **2007**, 25, 2164-70	2.2	314
149	Randomized trial of adjuvant 13-cis-retinoic acid and interferon alfa for patients with aggressive skin squamous cell carcinoma. *Journal of Clinical Oncology*, **2007**, 25, 1974-8	2.2	69
148	Identification of the retinoic acid-inducible Gprc5a as a new lung tumor suppressor gene. *Journal of the National Cancer Institute*, **2007**, 99, 1668-82	9.7	85
147	Proliferative changes in the bronchial epithelium of former smokers treated with retinoids. *Journal of the National Cancer Institute*, **2007**, 99, 1603-12	9.7	15
146	Repair capacity for UV light induced DNA damage associated with risk of nonmelanoma skin cancer and tumor progression. *Clinical Cancer Research*, **2007**, 13, 6532-9	12.9	41
145	Nucleotide excision repair pathway genes and oral premalignant lesions. *Clinical Cancer Research*, **2007**, 13, 3753-8	12.9	49
144	Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion. *Molecular Cancer Therapeutics*, **2007**, 6, 1962-72	6.1	109
143	Interaction index and different methods for determining drug interaction in combination therapy. *Journal of Biopharmaceutical Statistics*, **2007**, 17, 461-80	1.3	103
142	Asian ethnicity as a predictor of response in patients with non-small-cell lung cancer treated with gefitinib on an expanded access program. *Clinical Lung Cancer*, **2006**, 7, 326-31	4.9	27
141	Smoking affects treatment outcome in patients with advanced nonsmall cell lung cancer. *Cancer*, **2006**, 106, 2428-36	6.4	120
140	Overexpression of podoplanin in oral cancer and its association with poor clinical outcome. *Cancer*, **2006**, 107, 563-9	6.4	246
139	Nuclear factor-kappaB (NF-kappaB) is frequently expressed in lung cancer and preneoplastic lesions. *Cancer*, **2006**, 107, 2637-46	6.4	164
138	Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients. *Journal of the National Cancer Institute*, **2006**, 98, 441-50	9.7	188

137	Cyclin D1 gene polymorphism as a risk factor for oral premalignant lesions. *Carcinogenesis*, **2006**, 27, 2034-7	4.6	41
136	Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward. *Clinical Cancer Research* , **2006**, 12, 3661-97	12.9	235
135	Phase I/II study of docetaxel, cisplatin, and concomitant boost radiation for locally advanced squamous cell cancer of the head and neck. *Journal of Clinical Oncology*, **2006**, 24, 4163-9	2.2	54
134	Selenium accumulation in prostate tissue during a randomized, controlled short-term trial of l-selenomethionine: a Southwest Oncology Group Study. *Clinical Cancer Research*, **2006**, 12, 2178-84	12.9	45
133	Fenretinide activity in retinoid-resistant oral leukoplakia. *Clinical Cancer Research*, **2006**, 12, 3109-14	12.9	43
132	Reducing the "risk" of chemoprevention: defining and targeting high risk--2005 AACR Cancer Research and Prevention Foundation Award Lecture. *Cancer Research*, **2006**, 66, 2893-903	10.1	32
131	Identification and validation of differences in protein levels in normal, premalignant, and malignant lung cells and tissues using high-throughput Western Array and immunohistochemistry. *Cancer Research*, **2006**, 66, 11194-206	10.1	43
130	The cost of prostate cancer chemoprevention: a decision analysis model. *Cancer Epidemiology Biomarkers and Prevention*, **2006**, 15, 1485-9	4	26
129	Expression of Delta DNMT3B variants and its association with promoter methylation of p16 and RASSF1A in primary non-small cell lung cancer. *Cancer Research*, **2006**, 66, 8361-6	10.1	51
128	Decision analysis for prophylactic cranial irradiation for patients with small-cell lung cancer. *Journal of Clinical Oncology*, **2006**, 24, 3597-603	2.2	62
127	The prognostic role of loss of insulin-like growth factor-binding protein-3 expression in head and neck carcinogenesis. *Cancer Letters*, **2006**, 239, 136-43	9.9	34
126	A generalized response surface model with varying relative potency for assessing drug interaction. *Biometrics*, **2006**, 62, 986-95	1.8	41
125	Non-steroidal anti-inflammatory drugs and the risk of oral cancer: a nested case-control study. *Lancet, The*, **2005**, 366, 1359-66	40	49
124	Mortality risk from squamous cell skin cancer. *Journal of Clinical Oncology*, **2005**, 23, 759-65	2.2	322
123	Lymph node metastases from cutaneous squamous cell carcinoma of the head and neck. *Laryngoscope*, **2005**, 115, 1561-7	3.6	205
122	Loss of E-cadherin and p27 expression is associated with head and neck squamous tumorigenesis. *Cancer*, **2005**, 103, 952-9	6.4	25
121	Akt activation correlates with adverse outcome in tongue cancer. *Cancer*, **2005**, 104, 2430-6	6.4	97
120	A weight-adjusted Peto test when cause of death is not assigned. *Environmental and Ecological Statistics*, **2005**, 12, 95-113	2.2	

119	Implications of the prostate cancer prevention trial: a decision analysis model of survival outcomes. *Journal of Clinical Oncology*, **2005**, 23, 1911-20	2.2	29
118	Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. *Journal of Clinical Oncology*, **2005**, 23, 2544-55	2.2	497
117	9-cis-retinoic acid treatment increases serum concentrations of alpha-tocopherol in former smokers. *Clinical Cancer Research*, **2005**, 11, 2305-11	12.9	3
116	Increased retinoic acid receptor-beta4 correlates in vivo with reduced retinoic acid receptor-beta2 in esophageal squamous cell carcinoma. *Cancer Epidemiology Biomarkers and Prevention*, **2005**, 14, 826-94		21
115	Effects of 9-cis-retinoic acid on the insulin-like growth factor axis in former smokers. *Journal of Clinical Oncology*, **2005**, 23, 4439-49	2.2	10
114	Randomized phase II designs in cancer clinical trials: current status and future directions. *Journal of Clinical Oncology*, **2005**, 23, 4450-7	2.2	108
113	Aurora-A/STK15 T+91A is a general low penetrance cancer susceptibility gene: a meta-analysis of multiple cancer types. *Carcinogenesis*, **2005**, 26, 1368-73	4.6	124
112	Hypermethylation of the retinoic acid receptor-beta(2) gene in head and neck carcinogenesis. *Clinical Cancer Research*, **2004**, 10, 1733-42	12.9	111
111	Loss of Fhit expression in head and neck squamous cell carcinoma and its potential clinical implication. *Clinical Cancer Research*, **2004**, 10, 5554-7	12.9	16
110	Tetranucleotide microsatellite instability in surgical margins for prediction of local recurrence of head and neck squamous cell carcinoma. *Clinical Cancer Research*, **2004**, 10, 4022-8	12.9	29
109	Expression of hepatoma-derived growth factor is a strong prognostic predictor for patients with early-stage non-small-cell lung cancer. *Journal of Clinical Oncology*, **2004**, 22, 3230-7	2.2	96
108	The influence of resection and aneuploidy on mortality in oral leukoplakia. *New England Journal of Medicine*, **2004**, 350, 1405-13	59.2	81
107	Value of p16INK4a and RASSF1A promoter hypermethylation in prognosis of patients with resectable non-small cell lung cancer. *Clinical Cancer Research*, **2004**, 10, 6119-25	12.9	77
106	Longitudinal study of smoking patterns in relation to the development of smoking-related secondary primary tumors in patients with upper aerodigestive tract malignancies. *Cancer*, **2004**, 101, 2837-42	6.4	101
105	Gene expression screening of salivary gland neoplasms: molecular markers of potential histogenetic and clinical significance. *Journal of Molecular Diagnostics*, **2004**, 6, 180-90	5.1	37
104	Second primary tumors in patients with upper aerodigestive tract cancers: joint effects of smoking and alcohol (United States). *Cancer Causes and Control*, **2003**, 14, 131-8	2.8	123
103	Phase I study of weekly alternating therapy with irinotecan/cisplatin and etoposide/cisplatin for patients with small-cell lung cancer. *Clinical Lung Cancer*, **2003**, 5, 40-5	4.9	5
102	Estimation of k for the poly-k test with application to animal carcinogenicity studies. *Statistics in Medicine*, **2003**, 22, 2619-36	2.3	8

101	A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer. *Lung Cancer*, **2003**, 39, 55-61	5.9	173
100	The risk of second primary tumors after resection of stage I nonsmall cell lung cancer. *Annals of Thoracic Surgery*, **2003**, 76, 1001-7; discussion 1007-8	2.7	97
99	Retinoic acid receptor beta and telomerase catalytic subunit expression in bronchial epithelium of heavy smokers. *Journal of the National Cancer Institute*, **2003**, 95, 165-8	9.7	19
98	Cyclin D1 genotype, response to biochemoprevention, and progression rate to upper aerodigestive tract cancer. *Journal of the National Cancer Institute*, **2003**, 95, 198-205	9.7	84
97	Treatment of former smokers with 9-cis-retinoic acid reverses loss of retinoic acid receptor-beta expression in the bronchial epithelium: results from a randomized placebo-controlled trial. *Journal of the National Cancer Institute*, **2003**, 95, 206-14	9.7	75
96	Statistical Methods for Biomarker Analysis for Head and Neck Carcinogenesis and Prevention **2003**, 287-IV		
95	Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy. *Clinical Cancer Research*, **2003**, 9, 93-101	12.9	146
94	Breast tissue accumulation of retinamides in a randomized short-term study of fenretinide. *Clinical Cancer Research*, **2003**, 9, 2400-5	12.9	17
93	Phase II and biologic study of interferon alfa, retinoic acid, and cisplatin in advanced squamous skin cancer. *Journal of Clinical Oncology*, **2002**, 20, 364-70	2.2	113
92	The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma: potential for decreased toxicity and combination with biological therapy. *Cancer*, **2002**, 95, 340-53	6.4	29
91	Differential expression profiling of head and neck squamous carcinoma: significance in their phenotypic and biological classification. *Oncogene*, **2002**, 21, 8206-19	9.2	42
90	Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. *International Journal of Radiation Oncology Biology Physics*, **2002**, 53, 1097-105	4	1132
89	Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. *Journal of Clinical Oncology*, **2002**, 20, 2045-52	2.2	313
88	Phase II and Biologic Study of Interferon Alfa, Retinoic Acid, and Cisplatin in Advanced Squamous Skin Cancer. *Journal of Clinical Oncology*, **2002**, 20, 364-370	2.2	50
87	Aberrant promoter methylation of multiple genes in bronchial brush samples from former cigarette smokers. *Cancer Research*, **2002**, 62, 351-5	10.1	85
86	GATA-6 transcriptional regulation of 15-lipoxygenase-1 during NSAID-induced apoptosis in colorectal cancer cells. *Cancer Research*, **2002**, 62, 1178-83	10.1	32
85	Chromosome instability in lymphocytes: a potential indicator of predisposition to oral premalignant lesions. *Cancer Research*, **2002**, 62, 2813-8	10.1	28
84	Phase II study of paclitaxel, ifosfamide, and carboplatin in patients with recurrent or metastatic head and neck squamous cell carcinoma. *Cancer*, **2001**, 91, 1316-23	6.4	64

83	Uniform power method for sample size calculation in historical control studies with binary response. *Contemporary Clinical Trials*, **2001**, 22, 390-400		13
82	Ecarotene may not prevent second head and neck cancer. *Evidence-based Oncology*, **2001**, 2, 200-201		
81	Effects of N-(4-hydroxyphenyl)retinamide on hTERT expression in the bronchial epithelium of cigarette smokers. *Journal of the National Cancer Institute*, **2001**, 93, 1257-63	9.7	45
80	Long-term impact of smoking on lung epithelial proliferation in current and former smokers. *Journal of the National Cancer Institute*, **2001**, 93, 1081-8	9.7	82
79	Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer. *Journal of the National Cancer Institute*, **2001**, 93, 605-18	9.7	267
78	Design considerations for efficient prostate cancer chemoprevention trials. *Urology*, **2001**, 57, 205-12	1.6	15
77	Phase I and pharmacokinetic study of exatecan mesylate (DX-8951f): a novel camptothecin analog. *Journal of Clinical Oncology*, **2001**, 19, 1493-500	2.2	31
76	Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. *Journal of Clinical Oncology*, **2000**, 18, 3904-11	2.2	423
75	Extensions and Applications of Event Charts. *American Statistician*, **2000**, 54, 63	5	3
74	Cellular and humoral immune responses to adenovirus and p53 protein antigens in patients following intratumoral injection of an adenovirus vector expressing wild-type. P53 (Ad-p53). *Cancer Gene Therapy*, **2000**, 7, 530-6	5.4	59
73	Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer. *Journal of Clinical Oncology*, **2000**, 18, 609-22	2.2	297
72	Retinoic acid receptor-beta as a prognostic indicator in stage I non-small-cell lung cancer. *Journal of Clinical Oncology*, **2000**, 18, 2798-804	2.2	78
71	15-LOX-1: a novel molecular target of nonsteroidal anti-inflammatory drug-induced apoptosis in colorectal cancer cells. *Journal of the National Cancer Institute*, **2000**, 92, 1136-42	9.7	121
70	Extensions and Applications of Event Charts. *American Statistician*, **2000**, 54, 63-70	5	10
69	Hypermethylation of the death-associated protein (DAP) kinase promoter and aggressiveness in stage I non-small-cell lung cancer. *Journal of the National Cancer Institute*, **2000**, 92, 1511-6	9.7	217
68	Biochemopreventive therapy for patients with premalignant lesions of the head and neck and p53 gene expression. *Journal of the National Cancer Institute*, **2000**, 92, 69-73	9.7	40
67	Predicting cancer development in oral leukoplakia: ten years of translational research. *Clinical Cancer Research*, **2000**, 6, 1702-10	12.9	276
66	Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. *Journal of Clinical Oncology*, **1999**, 17, 976-83	2.2	1039

65	Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. *Journal of the National Cancer Institute*, **1999**, 91, 763-71	9.7	432
64	Re: Cancer chemoprevention: progress and promise. *Journal of the National Cancer Institute*, **1999**, 91, 563-5	9.7	5
63	Nuclear retinoid acid receptor beta in bronchial epithelium of smokers before and during chemoprevention. *Journal of the National Cancer Institute*, **1999**, 91, 1317-21	9.7	66
62	Galectin-1 and galectin-3 expression in human prostate tissue and prostate cancer. *Urological Research*, **1999**, 27, 362-7		45
61	A Phase I trial of intravenous melphalan, paclitaxel, and cisplatin plus granulocyte-colony stimulating factor in patients with suboptimal advanced epithelial ovarian carcinoma or peritoneal carcinoma. *Cancer*, **1999**, 86, 2291-2300	6.4	3
60	Accrual strategies for phase I trials with delayed patient outcome. *Statistics in Medicine*, **1999**, 18, 1155-69	2.3	40
59	Improved sentinel lymph node localization in patients with primary melanoma with the use of radiolabeled colloid. *Surgery*, **1998**, 124, 203-210	3.6	168
58	Nonparametric Regression Analysis of Longitudinal Data. *Journal of the American Statistical Association*, **1998**, 93, 1403-1418	2.8	109
57	Benzo[a]pyrene diol epoxide and bleomycin sensitivity and susceptibility to cancer of upper aerodigestive tract. *Journal of the National Cancer Institute*, **1998**, 90, 1393-9	9.7	53
56	Mutagen sensitivity as a predictor of tumor recurrence in patients with cancer of the upper aerodigestive tract. *Journal of the National Cancer Institute*, **1998**, 90, 243-5	9.7	29
55	Phenotype and genotype of advanced premalignant head and neck lesions after chemopreventive therapy. *Journal of the National Cancer Institute*, **1998**, 90, 1545-51	9.7	126
54	Cancer chemoprevention: progress and promise. *Journal of the National Cancer Institute*, **1998**, 90, 1514-28	9.7	124
53	Deletion in poly(ADP-ribose)polymerase pseudogene and lung cancer risk. *Carcinogenesis*, **1998**, 19, 93-8	4.6	10
52	Phase II study of neoadjuvant concurrent biochemotherapy in melanoma patients with local-regional metastases. *Melanoma Research*, **1998**, 8, 549-56	3.3	65
51	DNA damage in peripheral blood mononuclear cells correlates with response to biochemotherapy in melanoma. *Melanoma Research*, **1998**, 8, 145-8	3.3	3
50	Nitric oxide and neopterin levels and clinical response in stage III melanoma patients receiving concurrent biochemotherapy. *Melanoma Research*, **1998**, 8, 149-55	3.3	11
49	Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma. *Journal of Clinical Oncology*, **1998**, 16, 2253-60	2.2	478
48	Phase II trial of paclitaxel, ifosfamide, and cisplatin in patients with recurrent head and neck squamous cell carcinoma. *Journal of Clinical Oncology*, **1998**, 16, 1325-30	2.2	101

47	Suppression of retinoic acid receptor beta in non-small-cell lung cancer in vivo: implications for lung cancer development. *Journal of the National Cancer Institute*, **1997**, 89, 624-9	9.7	163
46	Clonal genetic alterations in the lungs of current and former smokers. *Journal of the National Cancer Institute*, **1997**, 89, 857-62	9.7	342
45	Low-dose isotretinoin versus beta-carotene to prevent oral carcinogenesis: long-term follow-up. *Journal of the National Cancer Institute*, **1997**, 89, 257-8	9.7	76
44	Phase I trial of alpha-tocopherol effects on 13-cis-retinoic acid toxicity. *Annals of Oncology*, **1997**, 8, 85-9	10.3	38
43	A Versatile One-Dimensional Distribution Plot: The BLiP Plot. *American Statistician*, **1997**, 51, 353-358	5	9
42	Evaluation of tyrosinase mRNA as a tumor marker in the blood of melanoma patients. *Journal of Clinical Oncology*, **1997**, 15, 2826-31	2.2	81
41	Likelihood-Weighted Confidence Intervals for the Difference of Two Binomial Proportions. *Biometrical Journal*, **1997**, 39, 387-407	1.5	9
40	Polyamine measurements in the uterine cervix. *Journal of Cellular Biochemistry*, **1997**, 67, 125-132	4.7	8
39	Cell kinetic analysis of intact rat colonic crypts by confocal microscopy and immunofluorescence. *Gastroenterology*, **1996**, 111, 1493-500	13.3	8
38	Phase II study of topotecan in patients with advanced non-small-cell lung cancer previously untreated with chemotherapy. *Journal of Clinical Oncology*, **1996**, 14, 503-13	2.2	97
37	Design and results of phase I cancer clinical trials: three-year experience at M.D. Anderson Cancer Center. *Journal of Clinical Oncology*, **1996**, 14, 287-95	2.2	83
36	Calcium carbonate treatment of diarrhoea in intestinal bypass patients. *European Journal of Gastroenterology and Hepatology*, **1996**, 8, 559-62	2.2	3
35	Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. *Nature Medicine*, **1996**, 2, 985-91	50.5	615
34	p53 expressions: predicting recurrence and second primary tumors in head and neck squamous cell carcinoma. *Journal of the National Cancer Institute*, **1996**, 88, 519-29	9.7	149
33	Expression of p53 oncoprotein in non-small-cell lung cancer: a favorable prognostic factor. *Journal of Clinical Oncology*, **1995**, 13, 1893-903	2.2	130
32	Prognostic value of size of lymph node metastases in patients with cutaneous melanoma. *Journal of Clinical Oncology*, **1995**, 13, 2361-8	2.2	83
31	Is follow-up of lung cancer patients after resection medically indicated and cost-effective?. *Annals of Thoracic Surgery*, **1995**, 60, 1563-70; discussion 1570-2	2.7	167
30	Suppression of retinoic acid receptor-beta in premalignant oral lesions and its up-regulation by isotretinoin. *New England Journal of Medicine*, **1995**, 332, 1405-10	59.2	339

29	p53 and retinoid chemoprevention of oral carcinogenesis. *Cancer Research*, **1995**, 55, 16-9	10.1	55
28	Randomized placebo-controlled trial of isotretinoin in chemoprevention of bronchial squamous metaplasia. *Journal of Clinical Oncology*, **1994**, 12, 937-45	2.2	157
27	Quality of life in adult survivors of lung, colon and prostate cancer. *Quality of Life Research*, **1994**, 3, 127-41	3.7	274
26	Relationship of P-glycoprotein and carcinoembryonic antigen expression in human colon carcinoma to local invasion, DNA ploidy, and disease relapse. *Cancer*, **1994**, 74, 2908-17	6.4	44
25	Micronuclei, a biomarker for chemoprevention trials: results of a randomized study in oral pre-malignancy. *International Journal of Cancer*, **1994**, 59, 457-9	7.5	31
24	A Better Confidence Interval for Kappa (Κ) on Measuring Agreement between Two Raters with Binary Outcomes. *Journal of Computational and Graphical Statistics*, **1994**, 3, 301-321	1.4	22
23	Surgical treatment of multiple brain metastases. *Journal of Neurosurgery*, **1993**, 79, 210-6	3.2	392
22	On Recensoring for Censored Paired Data. *Journal of the American Statistical Association*, **1993**, 88, 104	2.8	1
21	Comparison of low-dose isotretinoin with beta carotene to prevent oral carcinogenesis. *New England Journal of Medicine*, **1993**, 328, 15-20	59.2	326
20	On Recensoring for Censored Paired Data. *Journal of the American Statistical Association*, **1993**, 88, 104-118	2.8	2
19	Anticlastogenic effects of 13-cis-retinoic acid in vitro. *European Journal of Cancer*, **1992**, 29A, 137-40	7.5	10
18	Exploring the influence of multiple variables on the relationship of age to quality of life in women with breast cancer. *Journal of Clinical Epidemiology*, **1992**, 45, 473-85	5.7	85
17	The incidence of second primary tumors in long-term survivors of small-cell lung cancer. *Journal of Clinical Oncology*, **1992**, 10, 1519-24	2.2	73
16	The CARES: a generic measure of health-related quality of life for patients with cancer. *Quality of Life Research*, **1992**, 1, 19-29	3.7	202
15	Breast conservation versus mastectomy. Is there a difference in psychological adjustment or quality of life in the year after surgery?. *Cancer*, **1992**, 69, 1729-38	6.4	265
14	Quality of life assessment. An independent prognostic variable for survival in lung cancer. *Cancer*, **1991**, 67, 3131-5	6.4	295
13	Percutaneous nephrostomy tube placement: an outpatient procedure?. *Radiology*, **1991**, 179, 843-7	20.5	46
12	A Note on the Conditional Approach to Interval Estimation in the Calibration Problem. *Biometrics*, **1991**, 47, 1573	1.8	5

11	Jaw pain and tenderness levels during and after repeated sustained maximum voluntary protrusion. *Pain*, **1991**, 45, 17-22	8	19
10	Antibiotic prophylaxis for dental patients with joint prostheses? A decision analysis. *International Journal of Technology Assessment in Health Care*, **1990**, 6, 569-87	1.8	24
9	Second trimester maternal serum pregnancy specific beta-1 glycoprotein (SP-1) levels in normal and Down syndrome pregnancies. *American Journal of Medical Genetics Part A*, **1990**, 37, 114-8		17
8	Jaw pain and stiffness levels after repeated maximum voluntary clenching. *Journal of Dental Research*, **1989**, 68, 69-71	8.1	34
7	Electronic thermography of normal facial structures: a pilot study. *Oral Surgery, Oral Medicine, and Oral Pathology*, **1989**, 68, 346-51		21
6	A note on confidence limits for quartiles with right censored data. *Statistics in Medicine*, **1989**, 8, 1269-76	2.3	8
5	Evaluation of lopamidol and diatrizoate in excretory urography: a double-blind clinical study. *American Journal of Roentgenology*, **1988**, 151, 523-7	5.4	8
4	Simultaneous non-parametric confidence intervals for survival probabilities from censored data. *Statistics in Medicine*, **1986**, 5, 653-62	2.3	8
3	Bayesian Adaptive Methods for Clinical Trials		206
2	Immune evolution from preneoplasia to invasive lung adenocarcinomas and underlying molecular features		2
1	Bayesian Optimal Phase II Design for Randomized Clinical Trials. *Statistics in Biopharmaceutical Research*,1-19	1.2	0